Benzinga

Benzinga

Benzinga

martes, agosto 18

Prelude Therapeutics Inc

PRLDNASDAQ
Trade with Public
Trade with Public
$5.75
0.122.13%
al cierre: Aug 18, 5:00 PM EST
$5.75
N/A
After hour: 4:00 PM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el mar ago 11th, antes de la apertura del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Prelude Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prelude Therapeutics (PRLD).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

3S.Buy
2Buy
1Sell
Consensus RatingMarket Outperform# Analysts6Avg. Consensus PT$5Upside to Avg. PT-5.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 29, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$8
May 4, 2026D. Boral CapitalJason KolbertInitiateBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and raises the price target from $3 to $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved